Boston Sci acquires single-use uterine polyp remover from Distal Access

Resectr device--Courtesy of Distal Access

Boston Scientific is picking up a single-use device for the removal of uterine polyps in its acquisition of Distal Access’ gynecology and urology portfolio. The financial details of the deal were not disclosed.

The Resectr is a disposable, nonpowered, hand-held device that is compatible with various hysteroscopes. It is used for the treatment of uterine polyps in a doctor’s office, hospital or ambulatory surgery center. Uterine polyps, which can cause abnormal bleeding and infertility, affect as many as 80% of women. More than 400,000 polypectomies are done each year in the U.S., according to a statement.

“The Resectr device is exactly the type of innovation we need to help make healthcare more cost-effective and accessible for physicians and their patients," said David Pierce, senior vice president and president of Boston Scientific’s urology and pelvic health business, in the statement. "This acquisition is part of our commitment to advance comprehensive solutions for women's health that can help physicians provide high-quality care."

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The new acquisition will be folded into Boston Sci’s urology and pelvic health unit, which includes devices for the removal of uterine tissue and for the treatment of abnormal uterine bleeding, as well as pelvic floor reconstruction devices and urethral slings.

Boston Scientific has been on an acquisition spree of late, picking up Cosman Medical in July to boost its neuromodulation unit, stacking its endoscopy division with its $210 million acquisition of EndoChoice in September and snagging an in-development endoscopic tissue retractor from LumenR last month.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.